Please assess the completion status of the following clinical trial:

Trial Title: Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients scheduled to undergo non-myeloablative allogeneic stem-cell transplantation.~* meet institutional eligibility criteria for allogeneic SCT. Significant criteria are:~  * Renal function: Serum creatinine \<2; or calculated creatinine clearance \> 40 mL/min/1.72m2;~ * Hepatic function: Baseline direct bilirubin, ALT or AST lower than three times the upper limit of normal;~ * Pulmonary disease: FVC or FEV1 \> 40% predicted; Cardiac ejection fraction \> 40%.~Exclusion Criteria:~* Patients not expected to be available for follow-up in our institution for at least 100 days after the transplant~* Patients who are not undergoing standard non-myeloablative SCT with Flu/Bu conditioning and Tax/MTX GVHD prophylaxis~* Patients with uncontrolled bacterial, viral or fungal infections~* Patients who take strong inducers or inhibitors of the CYP450A4~* Patients receiving other investigational drugs for GVHD~* Women who are pregnant, plan to become pregnant or are breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1: 150mg Maraviroc (Type: EXPERIMENTAL): 150mg twice daily
- Phase 1: 300mg Maraviroc (Type: EXPERIMENTAL): 300mg twice daily
- Phase 2: 300mg Maraviroc (Type: EXPERIMENTAL): 300mg twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).